Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Bococizumab +/- rHuPH20 in Healthy and Hypercholesterolemic Adults
NCT02667223Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Feb 2016
- Primary completion
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bococizumab in hypercholesterolemia (5 cohorts), sponsored by Pfizer. Primary endpoints: Area Under the Curve to Infinity and Maximum Observed Concentration. Started Feb 2016; status: terminated.
02
Drugs
bococizumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02667223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02667223.